The present invention relates to novel compounds with a 5-(2-nitroethyl)-2,4,6-triaminopyrimidine structure used as antiparasitic agents, particularly against the parasites Trypanosoma brucei and Trypanosoma cruzi (Chagas disease), the cause of the diseases African human trypanosomiasis (or sleeping sickness).
Addressing target audiences and expressing needs
- Grants and Subsidies
- Collaboration
- Business Angels
Grants for further research or
investors
- Public or private funding institutions
- Research and Technology Organisations
- Private Investors
R&D, Technology and Innovation aspects
Current stage is a prototype potentially active on animal models
next step: confirmation of in vivo activity (some delvery systems are needed)
- Africa
- South America
- Europe

